RxDoctor Payments Data

Shawn Flynn, MD

Interventional Cardiology · Danville, KYNPI 1427272673

Payments from drug & device makers

$2,521in general payments, 2019–2025

Across 52 payments — averaging $48.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$2K
  • Novartis$109
  • Boston Scientific$79
  • Pfizer$58
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$44
  • Amgen$35
  • plus $187 from 8 others

What the payments were for

  • Travel & lodging$1,69067%
  • Food & beverage$83033%

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,521 in reported general payments places this provider in the 15th percentile of 129 interventional cardiology providers in Kentucky.

See all interventional cardiology providers in Kentucky

Medicare billing

Part B allowed, 2024
$84,527
Medicare patients
212
Services billed
946

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan143$140,185
JardianceEmpagliflozin74$71,413
EliquisApixaban76$62,153
Repatha SureclickEvolocumab62$40,874
XareltoRivaroxaban18$22,620
Nifedipine ErNifedipine139$2,818
Metoprolol Succinate277$2,403
Rosuvastatin Calcium130$1,283
Atorvastatin Calcium110$1,053
Valsartan46$795
Ezetimibe27$713
Carvedilol129$694
Losartan Potassium63$691
Amlodipine Besylate175$662
Spironolactone-HctzSpironolact/Hydrochlorothiazid17$624

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$109$140,185143 claims
PfizerEliquis$58$62,15376 claims
Johnson & JohnsonXarelto$19$22,62018 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 129 interventional cardiology providers in Kentucky.

Other interventional cardiology in Danville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →